AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
Portfolio Pulse from
AIM ImmunoTech has dosed the first new subject in its Phase 2 study of Ampligen and Imfinzi as a potential combination therapy for late-stage pancreatic cancer. The study includes subjects from Phase 1 who received the highest dose.
February 25, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AIM ImmunoTech has initiated a Phase 2 study for a combination therapy involving Ampligen and Imfinzi for late-stage pancreatic cancer. This includes subjects from Phase 1 who received the highest dose.
The initiation of a Phase 2 study is a significant step in drug development, indicating progress and potential for future success. Including high-dose Phase 1 subjects suggests promising initial results, which could positively impact AIM's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100